

EUROPEAN LUNG CANCER CONFERENCE 2016

ELCC 2016 13-16 April 2016

Dr. Solange Peters, Lausanne, Switzerland ESMO Scientific Committee Co-Chair

Dr. Wilfried Eberhardt, Essen, Germany

IASLC Scientific Committee Co-Chair



elcc2016.org

WELCOME TO THE 2016 ELCC CONFERENCE!

A collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists



A shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide



ELCC THROUGH THE YEARS

Geneva, 2008 - 2016





ELCC 2016



The results of an important collaborative effort

- # Participants: 2155
 - # Delegates: 1'854
 - # Press: 26
 - # Exhibitors: 231
 - # Industry Satellites: 44
- # Countries: 79



ELCC 2016



The results of an important collaborative effort

- # Sessions: 38
 - Educational: 16
 - Multidisciplinary Interactive Sessions (MIS): 4
 - Specialty: 5
 - Controversy: 2
 - Multidisciplinary Tumour Board: 1
 - Young Oncologists: 2
 - Special session: 1
 - Abstract-related: 7



ELCC 2016 - PROGRAMME HIGHLIGHTS

Educational sessions:

- 1. SCLC: Advances and state of the art
- 2. Mesothelioma: An update
- 3. Targeting T790M
- 4. Oligometastatic NSCLC
- 5. Targeting ALK
- 6. Smoking prevention and cessation
- 7. Radiotherapeutic issues of dose and fractionation
- 8. IASLC new staging system in NSCLC
- 9. Immunotherapy
- 10. How to improve stage III NSCLC multimodality treatment
- 11. New molecular targets of interest
- 12. Thymic malignancy: An update
- 13. Therapeutic emergencies in lung cancer
- 14. Collaborative efforts for rare molecularly defined NSCLC
- 15. WHO 2015
- 16. Minimally invasive local approaches





ELCC 2016 – PROGRAMME HIGHLIGHTS



Proffered paper (oral presentation) sessions:

- 1) New strategies for EGFR addicted NSCLC
- 2) Multidisciplinary management of thoracic malignancies
- 3) NSCLC targeted therapy and circulating biomarkers
- ESMO-IASLC Best Abstracts: The evolving landscape of immunotherapy



ELCC 2016 – PROGRAMME HIGHLIGHTS



ESMO-IASLC Best Abstracts: The evolving landscape of immunotherapy *Friday 15 April 2016 – 16:45-18:30*

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 antiprogrammed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC - *Don Gibbons et al*

Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial - *Myung-Ju Ahn et al*

Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses - *Suresh Ramalingam et al*



ELCC 2016 – PROGRAMME HIGHLIGHTS



KEYNOTE LECTURES

✓ Wednesday 13 April 2016

Heine H. Hansen Award Lecture

Suresh Senan, Amsterdam, Netherlands

✓ Thursday 14 April 2016

Basic immunotherapy for current and future cancer treatment strategies

John Haanen, Amsterdam, Netherlands

✓ Friday 15 April 2016

(History of) Platinum in lung cancer

Lawrence Einhorn, Indianapolis, IN, USA


✓ Saturday, 16 April 2016

Lung cancer care: The last and the next 5 years perspectives

Tony S.K. Mok, Hong Kong, China

HEINE H. HANSEN AWARD ESMO-IASLC 2nd HHH Award





The HHH Award acknowledges a lung cancer investigator who has made a special contribution to lung cancer research and education on an international basis

Heine Hoi Hansen, MD 1938 – 2001

- Pioneer researcher in the study of lung cancer
- Funding father of ESMO and IASLC
- IASLC President 1988 1991
- ESMO President 1996 1997
- Founder of IASLC Journal "Lung Cancer"

